Type 2 diabetes treatment pathways in New Zealand
Tuesday, 24 August 2021 8:26am
A nationwide study by a medical student, Joyce Guo, and researchers from the Pharmacoepidemiology Research Network has found that real-world type 2 diabetes treatment patterns are complex and not always consistent with guidelines.
Dual treatment increases risk of heart attack – study
Friday, 13 August 2021 11:59am
People using two different inhalers for common chronic lung diseases are more than 50 per cent more likely to have a heart attack than those on just one, new University of Otago-led research reveals.
Low adherence to diabetes medication concerning – Otago study
Thursday, 5 August 2021 12:39pm
Groups who suffer the highest burden of type 2 diabetes have the lowest level of adherence to effective medication to control it, a University of Otago study has found.
Researchers receive funding to investigate use and safety of anti-nausea drug in pregnancy
Wednesday, 28 July 2021 10:39am
Associate Professor Lianne Parkin and colleagues from the Pharmacoepidemiology Research Network have been awarded $1.2 million from the Health Research Council of New Zealand to investigate the use and safety of an anti-nausea drug during pregnancy.
What helps and hinders metformin adherence and persistence
Tuesday, 8 June 2021 8:48am
University of Otago research into what helps and hinders people with type 2 diabetes correctly taking, and continuing to take, metformin, features in today’s New Zealand Medical Journal.
Study tracks antidepressant use during pregnancy
Wednesday, 19 May 2021 2:59pm
Almost half of New Zealand women who take antidepressants in the months before getting pregnant, stop during their pregnancy, a new University of Otago study shows.
The Science of Medicines – a programme for tamariki
Tuesday, 9 February 2021 11:35am
The Ngāi Tahu Māori Health Research Unit's Dr Karyn Maclennan is currently piloting a new, innovative and hands-on education programme targeted at tamariki.
Long-acting bronchodilator use by patients with chronic lung disease and risk of acute coronary syndrome in real-world clinical practice
Wednesday, 27 January 2021 2:24pm
The use of two long-acting bronchodilator inhalers to treat chronic obstructive pulmonary disease (COPD) symptoms is associated with a higher risk of acute coronary syndrome (ACS, heart attack or unstable angina) than the use of just one long-acting bronchodilator according to recently published research by investigators from the Pharmacoepidemiology Research Network at the University of Otago.
Many Kiwis not taking cholesterol medication consistently
Thursday, 26 November 2020 4:19pm
More than half a million New Zealand adults are taking cholesterol-lowering medications, but a new University of Otago study reveals many are not taking them consistently.
Patterns of prescription medicine dispensing before and during pregnancy in New Zealand, 2005–2015
Wednesday, 10 June 2020 4:16pm
The use of prescription medicines by pregnant women in New Zealand increased substantially between 2005 and 2015.
Prescription medicines with potential for foetal harm: how often are they used during pregnancy in New Zealand?
Friday, 17 April 2020 11:03am
The use of prescription medicines during pregnancy that carry an increased risk of foetal harm was generally low, but increased in New Zealand over an 11-year period according to PhD candidate Dr Sarah Donald and other University of Otago researchers from the Pharmacoepidemiology Research Network.
Adherence to metformin in people with type 2 diabetes mellitus: results from the first New Zealand-wide study
Tuesday, 19 November 2019 2:08pm
In a national study, researchers from the Pharmacoepidemiology Research Network at the University of Otago have found sub-optimal levels of adherence to metformin, the recommended first-line drug used to treat type 2 diabetes.
Prevention of acute coronary events: are people with chronic obstructive pulmonary disease missing out?
Friday, 15 November 2019 4:57pm
There appears to be a particular reluctance to prescribe beta-blocker drugs to people with chronic obstructive pulmonary disease (COPD) who develop acute coronary syndrome (heart attacks and unstable angina) according to University of Otago researchers from the Pharmacoepidemiology Research Network.
PhD candidate receives award
Tuesday, 11 June 2019 8:42am
For the second year in a row, Sarah Donald has received a prize in the Dunedin School of Medicine’s postgraduate poster competition.
First paper published from PhD research
Tuesday, 6 November 2018 3:52pm
PhD candidate Sarah Donald and her supervisory team have published the first paper from her PhD research.
No increased risk of lung infections among infants using popular anti-reflux medicines
Tuesday, 18 September 2018 10:16am
New University of Otago research shows infants using popular anti-reflux medicines like omeprazole are not at increased risk of pneumonia or other lower respiratory tract infections, contrary to findings from other international studies.
PhD candidate receives award
Thursday, 31 May 2018 12:07pm
Sarah Donald has received a prize in the 2018 Dunedin School of Medicine postgraduate poster competition for a poster which outlines the process of generating a pregnancy cohort for medicine utilisation and safety studies in New Zealand.
Prescribing guidelines not always followed for patients on cholesterol-lowering drug
Friday, 4 May 2018 10:40am
New Zealand prescribers do not always follow guidelines when prescribing other medicines to patients taking simvastatin, according to University of Otago researchers from the Pharmacoepidemiology Research Network.
Chronic lung disease treatment in New Zealand often not consistent with international guidelines
Tuesday, 19 December 2017 10:53am
University of Otago researchers have found that the treatment of chronic obstructive pulmonary disease (COPD) in New Zealand frequently does not conform to international guidelines.
No evidence higher doses of cholesterol-lowering drug increase risk of acute kidney damage
Monday, 31 July 2017 3:37pm
New Zealanders taking a higher dose of simvastatin, one of the cholesterol-lowering statin drugs used to prevent heart attacks and strokes, do not appear to have a higher risk of acute kidney damage than those taking a lower dose, according to University of Otago researchers from the Pharmacoepidemiology Research Network.
Researchers funded to investigate possible adverse effect of a common lung disease treatment
Thursday, 15 June 2017 9:23am
The University of Otago’s Dr Lianne Parkin and colleagues will receive a Health Research Council grant to investigate whether particular drugs used to treat a common lung disease put people at greater risk of heart attacks.
Off-label prescription of proton pump inhibitors to New Zealand infants is common
Thursday, 4 May 2017 12:09pm
Off-label use of proton pump inhibitors is common among New Zealand infants, according to new University of Otago research.
Otago researchers receive new joint pharmaceuticals research funding
Thursday, 2 March 2017 4:32pm
Researchers from University of Otago are among the first recipients of two new grants from PHARMAC and the Health Research Council of New Zealand (HRC).
Disparities in insulin pump use by New Zealanders with type 1 diabetes: Otago research
Friday, 23 September 2016 11:32am
There are significant demographic and regional disparities in the use of insulin pumps in New Zealand, according to new University of Otago research.
